Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Alisi, Anna ^a   Ceccarelli, Sara ^a   Panera, Nadia ^a   Prono, Federica ^a   Petrini, Stefania ^a   De Stefanis, Cristiano ^a   Pezzullo, Marco ^a   Tozzi, Alberto ^a   Villani, Alberto ^a   Bedogni, Giorgio ^b   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Liver Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; KLOTHO CORECEPTOR; KLOTHO PROTEIN; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SCHOOL CHILD; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENE EXPRESSION REGULATION; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84879468929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067160     Document Type: Article

References (41)

1. Alisi A, Manco M, Vania A, Nobili V, (2009) Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 155: 469-474.
2. Brunt EM, (2010) Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 195-203.
3. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C, (2011) Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 17: 3082-3091.
4. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V, (2012) Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 44: 29-40.
5. Alisi A, Locatelli M, Nobili V, (2010) Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 13: 397-402.
6. Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, et al. (2013) Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 19: 83-92.
7. Angelin B, Larsson TE, Rudling M, (2012) Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab 16: 693-705.
8. Kliewer SA, Mangelsdorf DJ, (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91: 254S-257S.
9. Itoh N, (2010) Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342: 1-11.
10. Kurosu H, Kuro-O M, (2009) The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299: 72-78.
11. Jones SA, (2012) Physiology of FGF15/19. Adv Exp Med Biol 728: 171-182.
12. Kharitonenkov A, (2009) FGFs and metabolism. Curr Opin Pharmacol 9: 805-810.
13. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) FGF21 corrects obesity in mice. Endocrinology 149: 6018-6027.
14. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
15. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603.
16. Yan H, Xia M, Chang X, Xu Q, Bian H, et al. (2011) Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One 6: e24895.
17. Eren F, Kurt R, Ermis F, Atug O, Imeryuz N, et al. (2012) Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 45: 655-658.
18. Morris-Stiff G, Feldstein AE, (2010) Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol 53: 795-796.
19. Lohman TG, Roche AF, Martorell R (1988) Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books, 55-70.
20. Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, et al. (2002) Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 56: 171-180.
21. Manco M, Bedogni G, Marcellini M, Devito R, Ciampalini P, et al. (2008) Waist circumference correlates with liver fibrosis in children with non alcoholic steatohepatitis. Gut 57: 1283-1287.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
23. Koenker R (2005) Quantile Regression. Cambridge U. Press.
24. Royston P, Sauerbrei W (2008) Multivariable Model-building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, UK: Wiley.
25. Hilbe JM (2009) Logistic Regression Models. Boca Raton, FL: Chapman & Hall/CRC.
26. Long JS, Freese J (2008) Regression Models for Categorical Dependent Variables Using Stata. 2nd ed. College Station, TX: Stata Press.
27. Kurosu H, Kuro-O M, (2009) The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299: 72-78.
28. Shu G, Xie B, Ren F, Liu DC, Zhou J, et al. (2013) Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells. Cell Oncol (Dordr) 36: 121-129.
29. Reinehr T, Woelfle J, Wunsch R, Roth CL, (2012) Fibroblast Growth Factor 21 (FGF-21) and Its Relation to Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver in Children: A Longitudinal Analysis. J Clin Endocrinol Metab 97: 2143-2150.
30. Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, et al. (2012) Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 54: 700-713.
31. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH, (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51: 371-379.
32. Chartoumpekis DV, Ziros PG, Psyrogiannis AI, Papavassiliou AG, Kyriazopoulou VE, et al. (2011) Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes 60: 2465-2473.
33. Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, et al. (2012) TNF-α Represses β-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway. Endocrinology 153: 4238-4245.
34. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, et al. (2011) Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 41: 390-396.
35. Schreuder TC, Marsman HA, Lenicek M, van WervenJR, Nederveen AJ, et al. (2010) The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G440-445.
36. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, et al. (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7: e38438.
37. Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, et al. (2012) Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS One 7: e52711.
38. Adams AC, Cheng CC, Coskun T, Kharitonenkov A, (2012) FGF21 Requires βklotho to Act In Vivo. PLoS One 7: e49977.
39. Yang C, Jin C, Li X, Wang F, McKeehan WL, et al. (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7: e33870.
40. Chen L, Liu H, Liu J, Zhu Y, Xu L, et al. (2013) Klotho Endows Hepatoma Cells with Resistance to Anoikis via VEGFR2/PAK1 Activation in Hepatocellular Carcinoma. PLoS One 8: e58413.
41. Huang CL, (2012) Regulation of ion channels by secreted Klotho. Adv Exp Med Biol 728: 100-106.